Improved Hemodynamic Tolerance of Intermittent Hemodialysis Sessions in Intensive Care Unite Using Citrate- vs Acetate-based Dialysate

Last updated: January 2, 2026
Sponsor: Centre Hospitalier de Bethune
Overall Status: Active - Recruiting

Phase

N/A

Condition

Dizzy/fainting Spells

Vascular Diseases

Circulation Disorders

Treatment

CITRATE based dialysate

ACETATE based dialysate

Clinical Study ID

NCT05936710
2023-01
  • Ages > 18
  • All Genders

Study Summary

During intermittent hemodialysis (IHD), the occurrence of intradialytic hemodynamic instability (IHI) is frequent in ICU and impacted morbidity and mortality. Bicarbonate dialysate buffer improves hemodynamic tolerance compared to acetate dialysate buffer. However, bicarbonate dialysate buffer still contains a lower concentration of acetate, which could contribute to hemodynamic instability. Recently, citrate-based dialysate in bicarbonate hemodialysis instead of acetate have been proposed. They have the appropriate authorizations for routine use. The aim of this study is to compare acetate- vs citrate-based dialysate in terms of hemodynamic tolerance and effectiveness.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient ≥ 18 years old

  • Patient hospitalized in an intensive care unit

  • Patient with acute renal failure defined by a KDIGO stage ≥ 1 and suspectednon-obstructive

  • Patient at risk of per dialytic hypotension (capillary refill time ≥ 3 secondsand/or cardiovascular SOFA ≥ 1 and/or lactatemia > 2mmol/L)

  • Indication for Extra Renal Replacement Therapy with IHD.

Exclusion

Exclusion Criteria:

  • Pregnant or breastfeeding woman

  • Known chronic renal insufficiency of any stage

  • Cardio-renal and hepato renal syndrome

  • Unstable hemodynamic state: refractory shock

  • Patient included in another interventional study likely to modify the hemodynamicstate

  • Patient deprived of liberty

  • Patient under guardianship or curatorship

  • Patient not affiliated to a social security system

Study Design

Total Participants: 48
Treatment Group(s): 2
Primary Treatment: CITRATE based dialysate
Phase:
Study Start date:
December 07, 2023
Estimated Completion Date:
July 31, 2027

Connect with a study center

  • Centre Hospitalier Béthune

    Béthune, 62408
    France

    Site Not Available

  • Centre Hospitalier Béthune

    Béthune 3033002, 62408
    France

    Active - Recruiting

  • Centre Hospitalier Universitaire de Caen

    Caen, 14000
    France

    Site Not Available

  • CHU

    Caen 3029241,
    France

    Active - Recruiting

  • Centre Hospitalier Universitaire de Dijon

    Dijon 3021372,
    France

    Active - Recruiting

  • CHRU Nancy

    Nancy 2990999,
    France

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.